Why the study?
Does the addition of doxorubicin improve survival in patients with advanced ovarian cancer?
Does the addition of doxorubicin improve survival in patients with advanced ovarian cancer?
Answers are grounded in this paper and cite their sources.
Supports adding doxorubicin to regimens for advanced ovarian cancer; confirms benefit magnitude similar to platinum.
PURPOSE: Our study examined the impact of the addition of doxorubicin to ovarian cancer regimens in general, while removing the confounding influence of other drugs. MATERIALS AND METHODS: We performed an overview using the data from two large analyses, the Advanced Ovarian Cancer Trialists Group (AOCTG [Br Med J 303:884-893, 1991] and Williams et al [Seminars in Oncol 19:120-128, 1992 (suppl 2)]) and the Ovarian Cancer Meta-Analysis Project (OCMP [J Clin Oncol 9:1668-1674, 1991]). RESULTS: Our data suggest that the addition of doxorubicin significantly improves survival (hazards ratio, 0.85; 95% confidence interval [CI], 0.76 to 0.95; P = .003) and that the size of this benefit is of a similar magnitude to that of platinum. CONCLUSION: The implication of our results is that the basic drugs for the standard treatment of advanced ovarian should be a combination of platinum and doxorubicin. The addition of an alkylating agent may add toxicity and lead to a dose reduction of these two drugs. In view of recent data on combination therapy with paclitaxel and platinum, it would be appropriate to compare this regimen with a combination of doxorubicin and platinum.
No takes yet. Share an insight, caveat, or question.
A’Hern et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: